Study points to a strategy for inhibiting hyper-progression of melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

FDA expands label for Novartis and Roche’s blockbuster, converts EMD Serono’s NSCLC drug to full approval

The FDA on Friday signed off on an expanded label for Novartis and Roche’s blockbuster Xolair (omalizumab) and on Thursday converted the accelerated to full

February 17, 2024

What to Know About President Trump’s Order Targeting Transgender Rights

An executive order President Trump signed on his first day back in office offers a new federal government definition of the sexes that could have

January 26, 2025

Obesity at cancer diagnosis linked to higher risk of death in children

A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying.

January 13, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.